Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 68

1.

Lithocholic acid, a bacterial metabolite reduces breast cancer cell proliferation and aggressiveness.

Mikó E, Vida A, Kovács T, Ujlaki G, Trencsényi G, Márton J, Sári Z, Kovács P, Boratkó A, Hujber Z, Csonka T, Antal-Szalmás P, Watanabe M, Gombos I, Csoka B, Kiss B, Vígh L, Szabó J, Méhes G, Sebestyén A, Goedert JJ, Bai P.

Biochim Biophys Acta Bioenerg. 2018 Sep;1859(9):958-974. doi: 10.1016/j.bbabio.2018.04.002. Epub 2018 Apr 13.

PMID:
29655782
2.

Significance of serological markers in the disease course of ulcerative colitis in a prospective clinical cohort of patients.

Kovacs G, Sipeki N, Suga B, Tornai T, Fechner K, Norman GL, Shums Z, Antal-Szalmas P, Papp M.

PLoS One. 2018 Mar 28;13(3):e0194166. doi: 10.1371/journal.pone.0194166. eCollection 2018.

3.

Loss of tolerance to gut immunity protein, glycoprotein 2 (GP2) is associated with progressive disease course in primary sclerosing cholangitis.

Tornai T, Tornai D, Sipeki N, Tornai I, Alsulaimani R, Fechner K, Roggenbuck D, Norman GL, Veres G, Par G, Par A, Szalay F, Lakatos PL, Antal-Szalmas P, Papp M.

Sci Rep. 2018 Jan 10;8(1):399. doi: 10.1038/s41598-017-18622-1.

4.

Functional polymorphisms of innate immunity receptors are not risk factors for the non-SBP type bacterial infections in cirrhosis.

Dinya T, Tornai T, Vitalis Z, Tornai I, Balogh B, Tornai D, Antal-Szalmas P, Sumegi A, Andrikovics H, Bors A, Tordai A, Papp M.

Liver Int. 2018 Jul;38(7):1242-1252. doi: 10.1111/liv.13664. Epub 2018 Jan 17.

PMID:
29235260
5.

Gut barrier failure biomarkers are associated with poor disease outcome in patients with primary sclerosing cholangitis.

Tornai T, Palyu E, Vitalis Z, Tornai I, Tornai D, Antal-Szalmas P, Norman GL, Shums Z, Veres G, Dezsofi A, Par G, Par A, Orosz P, Szalay F, Lakatos PL, Papp M.

World J Gastroenterol. 2017 Aug 7;23(29):5412-5421. doi: 10.3748/wjg.v23.i29.5412.

6.

Laboratory characterization of leukemic cell procoagulants.

Hudák R, Debreceni IB, Deák I, Szabó GG, Hevessy Z, Antal-Szalmás P, Osterud B, Kappelmayer J.

Clin Chem Lab Med. 2017 Jul 26;55(8):1215-1223. doi: 10.1515/cclm-2017-0021.

PMID:
28593927
7.

Lectin-complement pathway molecules are decreased in patients with cirrhosis and constitute the risk of bacterial infections.

Foldi I, Tornai T, Tornai D, Sipeki N, Vitalis Z, Tornai I, Dinya T, Antal-Szalmas P, Papp M.

Liver Int. 2017 Jul;37(7):1023-1031. doi: 10.1111/liv.13368. Epub 2017 Feb 28.

PMID:
28109038
8.

Presepsin teardown - pitfalls of biomarkers in the diagnosis and prognosis of bacterial infection in cirrhosis.

Papp M, Tornai T, Vitalis Z, Tornai I, Tornai D, Dinya T, Sumegi A, Antal-Szalmas P.

World J Gastroenterol. 2016 Nov 7;22(41):9172-9185.

9.

Human Epididymis Protein 4: A Novel Serum Inflammatory Biomarker in Cystic Fibrosis.

Nagy B Jr, Nagy B, Fila L, Clarke LA, Gönczy F, Bede O, Nagy D, Újhelyi R, Szabó Á, Anghelyi A, Major M, Bene Z, Fejes Z, Antal-Szalmás P, Bhattoa HP, Balla G, Kappelmayer J, Amaral MD, Macek M Jr, Balogh I.

Chest. 2016 Sep;150(3):661-72. doi: 10.1016/j.chest.2016.04.006. Epub 2016 Apr 19.

PMID:
27105680
10.

Macrophage activation marker, soluble CD163, is an independent predictor of short-term mortality in patients with cirrhosis and bacterial infection.

Tornai T, Vitalis Z, Sipeki N, Dinya T, Tornai D, Antal-Szalmas P, Karanyi Z, Tornai I, Papp M.

Liver Int. 2016 Nov;36(11):1628-1638. doi: 10.1111/liv.13133. Epub 2016 May 5.

PMID:
27031405
11.

Cystatin C as a potential predictor of osteoprotegerin levels in healthy men, a cross-sectional, observational study.

Kulcsar-Jakab E, Petho Z, Pap Z, Kalina E, Foldesi R, Balogh A, Antal-Szalmas P, Bhattoa HP.

BMC Musculoskelet Disord. 2015 Aug 28;16:227. doi: 10.1186/s12891-015-0684-1.

12.

Risk Matrix for Prediction of Disease Progression in a Referral Cohort of Patients with Crohn's Disease.

Lakatos PL, Sipeki N, Kovacs G, Palyu E, Norman GL, Shums Z, Golovics PA, Lovasz BD, Antal-Szalmas P, Papp M.

J Crohns Colitis. 2015 Oct;9(10):891-8. doi: 10.1093/ecco-jcc/jjv127. Epub 2015 Jul 18.

PMID:
26188353
13.

Rediscovery of the Anti-Pancreatic Antibodies and Evaluation of their Prognostic Value in a Prospective Clinical Cohort of Crohn's Patients: The Importance of Specific Target Antigens [GP2 and CUZD1].

Papp M, Sipeki N, Tornai T, Altorjay I, Norman GL, Shums Z, Roggenbuck D, Fechner K, Stöcker W, Antal-Szalmas P, Veres G, Lakatos PL.

J Crohns Colitis. 2015 Aug;9(8):659-68. doi: 10.1093/ecco-jcc/jjv087. Epub 2015 May 12.

PMID:
25968583
14.

Human epididymis protein 4 (HE4) in laboratory medicine and an algorithm in renal disorders.

Kappelmayer J, Antal-Szalmás P, Nagy B Jr.

Clin Chim Acta. 2015 Jan 1;438:35-42. doi: 10.1016/j.cca.2014.07.040. Epub 2014 Aug 13. Review.

PMID:
25127713
15.

MLH1 and MSH2 mutation screening in HNPCC families of Hungary - Two new MMR gene mutations.

Tanyi M, Olasz J, Tanyi JL, Tóth L, Antal-Szalmás P, Ress Z, Bubán T, Palatka K, András C, Urbancsek H, Garami Z, Csuka O, Damjanovich L.

Eur J Surg Oncol. 2014 Nov;40(11):1445-52. doi: 10.1016/j.ejso.2014.07.032. Epub 2014 Jul 24.

PMID:
25107687
16.

Serum human epididymis protein 4 (HE4) as a tumor marker in men with lung cancer.

Nagy B Jr, Bhattoa HP, Steiber Z, Csobán M, Szilasi M, Méhes G, Müller M, Lázár J, Kappelmayer J, Antal-Szalmás P.

Clin Chem Lab Med. 2014 Nov;52(11):1639-48. doi: 10.1515/cclm-2014-0041.

PMID:
24829194
17.

Immune dysfunction in cirrhosis.

Sipeki N, Antal-Szalmas P, Lakatos PL, Papp M.

World J Gastroenterol. 2014 Mar 14;20(10):2564-77. doi: 10.3748/wjg.v20.i10.2564. Review.

18.

Serum thymidine kinase activity: analytical performance, age-related reference ranges and validation in chronic lymphocytic leukemia.

Szánthó E, Bhattoa HP, Csobán M, Antal-Szalmás P, Újfalusi A, Kappelmayer J, Hevessy Z.

PLoS One. 2014 Mar 12;9(3):e91647. doi: 10.1371/journal.pone.0091647. eCollection 2014.

19.

Autologous dendritic cell based adoptive immunotherapy of patients with colorectal cancer-A phase I-II study.

Hunyadi J, András C, Szabó I, Szántó J, Szluha K, Sipka S, Kovács P, Kiss A, Szegedi G, Altorjay I, Sápy P, Antal-Szalmás P, Tóth L, Fazekas G, Rajnavölgyi É.

Pathol Oncol Res. 2014 Apr;20(2):357-65. doi: 10.1007/s12253-013-9704-3. Epub 2013 Oct 28.

PMID:
24163303
20.

High prevalence of IgA class anti-neutrophil cytoplasmic antibodies (ANCA) is associated with increased risk of bacterial infection in patients with cirrhosis.

Papp M, Sipeki N, Vitalis Z, Tornai T, Altorjay I, Tornai I, Udvardy M, Fechner K, Jacobsen S, Teegen B, Sumegi A, Veres G, Lakatos PL, Kappelmayer J, Antal-Szalmas P.

J Hepatol. 2013 Sep;59(3):457-66. doi: 10.1016/j.jhep.2013.04.018. Epub 2013 Apr 29.

PMID:
23639483

Supplemental Content

Loading ...
Support Center